Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT1 | P26358 | 6/20 | 0.65 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.65 |
| ▸ | DNMT3B | Q9UBC3 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | PNP | P00491 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.50 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
| ▸ | TK1 | P04183 | 1/20 | 0.49 |
| ▸ | FPR2 | P25090 | 1/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL530280 | 1.00 | DNMT1 (0.65) | DNMT1ADRB1DNMT3BLMNASMN1; SMN2 | |
| Phosphoric Acid SCHEMBL6460717 | 0.95 | DNMT1 (0.60) | DNMT1ADRB1DNMT3BLMNASMN1; SMN2 | |
| SCHEMBL5983766 | 0.89 | DNMT1 (0.66) | DNMT1ADRB1DNMT3BLMNASMN1; SMN2 | |
| SCHEMBL5983760 | 0.89 | DNMT1 (0.66) | DNMT1ADRB1DNMT3BLMNASMN1; SMN2 | |
| SCHEMBL24141674 | 0.86 | DNMT1 (0.63) | DNMT1ADRB1DNMT3BLMNASMN1; SMN2 | |
| SCHEMBL22299584 | 0.86 | DNMT1 (0.64) | DNMT1ADRB1DNMT3BLMNASMN1; SMN2 | |
| Ibacitabine SCHEMBL244921 | 0.86 | DNMT1 (0.63) | DNMT1ADRB1DNMT3BLMNASMN1; SMN2 | |
| Cytochlor SCHEMBL21423105 | 0.86 | DNMT1 (0.63) | DNMT1ADRB1DNMT3BLMNASMN1; SMN2 | |
| Ibacitabine SCHEMBL21423094 | 0.86 | DNMT1 (0.63) | DNMT1ADRB1DNMT3BLMNASMN1; SMN2 | |
| SCHEMBL9692250 | 0.86 | DNMT1 (0.63) | DNMT1ADRB1DNMT3BLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 625 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125669-A1 | METHODS AND COMPOSITIONS FOR SYNTHETIC EVOLUTION | UNIVERSITAT POMPEU FABRA (ES) | 2026-05-07 | — | — | US | claimed |
| US-20250263678-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | REJUVENATION TECHNOLOGIES, INC. (US) | 2025-08-21 | — | — | US | claimed |
| EP-4599047-A1 | METHODS AND COMPOSITIONS FOR SYNTHETIC EVOLUTION | Universitat Pompeu Fabra (ES) | 2025-08-13 | — | — | EP | claimed |
| WO-2025024123-A1 | NOVEL CITICOLINE DERIVATIVES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-01-30 | — | — | WO | claimed |
| WO-2024074709-A1 | METHODS AND COMPOSITIONS FOR SYNTHETIC EVOLUTION | UNIVERSITAT POMPEU FABRA (ES) | 2024-04-11 | — | — | WO | claimed |
| EP-4271389-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | Rejuvenation Technologies Inc. (US) | 2023-11-08 | — | — | EP | claimed |
| CN-116916936-A | Compositions and methods for delivering RNA | 再生技术有限责任公司 | 2023-10-20 | — | — | CN | claimed |
| EP-4114417-A2 | THERAPEUTIC AGENTS AND CONJUGATES THEREOF | Beijing Xuanyi Pharmasciences Co., Ltd. (CN) | 2023-01-11 | — | — | EP | claimed |
| CN-115427051-A | Therapeutic agents and conjugates thereof | 北京轩义医药科技有限公司 | 2022-12-02 | — | — | CN | claimed |
| WO-2022147039-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | REJUVENATION TECHNOLOGIES INC. (US) | 2022-07-07 | — | — | WO | claimed |
| WO-2003057822-A2 | MODULATION OF IMMUNOSTIMULATORY PROPERTIES OF OLIGONUCLEOTIDE-BASED COMPOUNDS BY OPTIMAL PRESENTATION OF 5' ENDS | HYBRIDON, INC. (US) | 2003-07-17 | — | — | WO | claimed |
| WO-2003035836-A2 | MODULATION OF IMMUNOSTIMULATORY PROPERTIES OF OLIGONUCLEOTIDE-BASED COMPOUNDS BY OPTIMAL PRESENTATION OF 5' ENDS | HYBRIDON INC. (US) | 2003-05-01 | — | — | WO | claimed |
| US-6548252-B1 | Electrochemically analyzing samples from selected areas of the body of a living organism for elevated free levels of nucleotide excision products resulting from DNA or RNA damage | ESA, INC. | 2003-04-15 | — | — | US | claimed |
| EP-1226238-A2 | METHOD FOR CREATING DIVERGENT POPULATIONS OF NUCLEIC ACID MOLECULES AND PROTEINS | Cytos Biotechnology AG (CH) | 2002-07-31 | — | — | EP | claimed |
| WO-2001030989-A2 | METHOD FOR CREATING DIVERGENT POPULATIONS OF NUCLEIC ACID MOLECULES AND PROTEINS | CYTOS BIOTECHNOLOGY AG (US) | 2001-05-03 | — | — | WO | claimed |
| US-6132776-A | ASSAYS FOR IDENTIFYING NUCLEOSIDE ANALOGS FOR THERAPY OF HIV(HUMAN IMMUNODEFICIENCY VIRUS)-INFECTED INDIVIDUALS | UNIVERSITY OF WASHINGTON (US) | 2000-10-17 | — | — | US | claimed |
| EP-0767842-B1 | METHODS OF SCREENING FOR NUCLEOSIDE ANALOGS THAT ARE INCORPORATED BY HIV REVERSE TRANSCRIPTASE AND CAUSE INCORRECT BASE PAIRING | UNIV WASHINGTON (US) | 2000-09-27 | — | — | EP | claimed |
| EP-1004675-A2 | Methods of screening for nucleoside analogs that are incorporated by HIV reverse transcriptase and cause incorrect base pairing | DARWIN MOLECULAR CORPORATION (US) | 2000-05-31 | — | — | EP | claimed |
| EP-0767842-A1 | METHODS OF SCREENING FOR NUCLEOSIDE ANALOGS THAT ARE INCORPORATED BY HIV REVERSE TRANSCRIPTASE AND CAUSE INCORRECT BASE PAIRING | DARWIN MOLECULAR CORPORATION (US) | 1997-04-16 | — | — | EP | claimed |
| WO-1996000797-A1 | METHODS OF SCREENING FOR NUCLEOSIDE ANALOGS THAT ARE INCORPORATED BY HIV REVERSE TRANSCRIPTASE AND CAUSE INCORRECT BASE PAIRING | DARWIN MOLECULAR CORP (US) | 1996-01-11 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250263678-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | RNASE1, POLRMT, TERT | DNMT1 384/4885ADRB1 4067/4885DNMT3B 303/4885 |
| US-20260125669-A1 | METHODS AND COMPOSITIONS FOR SYNTHETIC EVOLUTION | POLM, CPSF6, CPSF1 | DNMT1 3336/4885ADRB1 4865/4885DNMT3B 2402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.